Organic Letters
Letter
(14) Prepared from methyl 4-(chloroformyl)butyrate in six steps:
(a) Gotz, K.; Liermann, J. C.; Thines, E.; Anke, H.; Opatz, T. Org.
Biomol. Chem. 2010, 8, 2123. (b) Treilhou, M.; Fauve, A.; Pougny, J.
R.; Prome, J. C.; Veschambre, H. J. Org. Chem. 1992, 57, 3203.
(c) Chemin, D.; Linstrumelle, G. Tetrahedron 1992, 48, 1943−1952.
(d) Rodriguez, A. R.; Spur, B. W. Tetrahedron Lett. 2012, 53, 86−89.
(15) (a) Review: Alcaide, B.; Almendros, P.; Alonso, J. M. Org.
Biomol. Chem. 2011, 9, 4405. (b) Harkat, H.; Weibel, J.-M.; Pale, P.
Tetrahedron Lett. 2007, 48, 1439.
(16) Smith, J. P.; Haddad, E. V.; Downey, J. D.; Breyer, R. M.;
Boutaud, O. Arteriosclerosis Thrombosis and Vascular Biology 2010, 30,
E219.
(17) Data are presented as mean SD from four healthy volunteers.
Symbols show differences between the different groups; ***, p <
0.001.
provide opportunity for further biological study of these
interesting and unusual eicosanoids.
ASSOCIATED CONTENT
* Supporting Information
■
S
The Supporting Information is available free of charge on the
General experimental procedures, characterization data,
and 1H and 13C NMR spectra of new compounds
AUTHOR INFORMATION
■
Corresponding Author
ORCID
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
This research was supported by the National Institutes of
Health (5R01 GM115722 to G.A.S. and 5R01 GM076592 to
C.S.). J.A.G.-B. was supported by a postdoctoral award from
the American Heart Association (16POST30690001).
REFERENCES
(1) Funk, C. D. Science 2001, 294, 1871.
(2) (a) Harizi, H.; Corcuff, J. B.; Gualde, N. Trends Mol. Med. 2008,
14, 461. (b) Dennis, E. A.; Norris, P. C. Nat. Rev. Immunol. 2015, 15,
511.
■
(3) (a) Haeggstrom, J. Z.; Funk, C. D. Chem. Rev. 2011, 111, 5866.
(b) Rouzer, C. A.; Marnett, L. J. Chem. Rev. 2011, 111, 5899.
(4) Griesser, M.; Suzuki, T.; Tejera, N.; Mont, S.; Boeglin, W. E.;
Pozzi, A.; Schneider, C. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 6945.
(5) Schneider, C.; Boeglin, W. E.; Yin, H. Y.; Stec, D. F.; Voehler, M.
J. Am. Chem. Soc. 2006, 128, 720.
́
(6) Gimenez-Bastida, J. A.; Shibata, T.; Uchida, K.; Schneider, C.
FASEB J. 2017, 31, 1867.
(7) Gimenez-Bastida, J. A.; Suzuki, T.; Sprinkel, K. C.; Boeglin, W.
E.; Schneider, C. Prostaglandins Other Lipid Mediators 2017, 132, 41−
46.
(8) For a review on the stereoselectivity of alkynyl metals to 2-
substituted aldehydes, see: Guillarme, S.; Ple, K.; Banchet, A.; Liard,
A.; Haudrechy, A. Chem. Rev. 2006, 106, 2355.
(9) For an example of a similar cyclization-oxidation sequence, see:
Woo, S. K.; Lee, E. J. Am. Chem. Soc. 2010, 132, 4564.
(10) Furrow, M. E.; Schaus, S. E.; Jacobsen, E. N. J. Org. Chem.
1998, 63, 6776.
(11) Trygstad, T. M.; Pang, Y. C.; Forsyth, C. J. J. Org. Chem. 2009,
74, 910.
(12) Trost, B. M.; Machacek, M. R.; Faulk, B. D. J. Am. Chem. Soc.
2006, 128, 6745.
(13) Prepared from hexanoyl chloride in six steps: (a) Marron, B. E.;
Spanevello, R. A.; Elisseou, M. E.; Serhan, C. N.; Nicolaou, K. C. J.
Org. Chem. 1989, 54, 5522. (b) Matsumura, K.; Hashiguchi, S.;
Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1997, 119, 8738.
(c) Nicolaou, K. C.; Veale, C. A.; Webber, S. E.; Katerinopoulos,
H. J. Am. Chem. Soc. 1985, 107, 7515. (d) Suzuki, M.; Kiho, T.;
Tomokiyo, K.; Furuta, K.; Fukushima, S.; Takeuchi, Y.; Nakanishi,
M.; Noyori, R. J. Med. Chem. 1998, 41, 3084.
C
Org. Lett. XXXX, XXX, XXX−XXX